Tandem Other Current Assets vs Common Stock Total Equity Analysis
TNDM Stock | USD 30.81 0.07 0.23% |
Tandem Diabetes financial indicator trend analysis is much more than just breaking down Tandem Diabetes Care prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Tandem Diabetes Care is a good investment. Please check the relationship between Tandem Diabetes Other Current Assets and its Common Stock Total Equity accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tandem Diabetes Care. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
Other Current Assets vs Common Stock Total Equity
Other Current Assets vs Common Stock Total Equity Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Tandem Diabetes Care Other Current Assets account and Common Stock Total Equity. At this time, the significance of the direction appears to have very week relationship.
The correlation between Tandem Diabetes' Other Current Assets and Common Stock Total Equity is 0.29. Overlapping area represents the amount of variation of Other Current Assets that can explain the historical movement of Common Stock Total Equity in the same time period over historical financial statements of Tandem Diabetes Care, assuming nothing else is changed. The correlation between historical values of Tandem Diabetes' Other Current Assets and Common Stock Total Equity is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Current Assets of Tandem Diabetes Care are associated (or correlated) with its Common Stock Total Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock Total Equity has no effect on the direction of Other Current Assets i.e., Tandem Diabetes' Other Current Assets and Common Stock Total Equity go up and down completely randomly.
Correlation Coefficient | 0.29 |
Relationship Direction | Positive |
Relationship Strength | Very Weak |
Other Current Assets
Assets expected to be converted into cash, sold, or consumed either in one year or in the operating cycle, which are not included under standard current asset categories.Common Stock Total Equity
The total value of common stock equity held by shareholders, representing their ownership interest in the company.Most indicators from Tandem Diabetes' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Tandem Diabetes Care current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tandem Diabetes Care. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. At this time, Tandem Diabetes' Selling General Administrative is very stable compared to the past year. As of the 22nd of November 2024, Tax Provision is likely to grow to about 2.5 M, while Enterprise Value Over EBITDA is likely to drop (12.28).
2021 | 2023 | 2024 (projected) | Interest Expense | 4.3M | 9.9M | 6.0M | Depreciation And Amortization | 13.8M | 15.7M | 8.0M |
Tandem Diabetes fundamental ratios Correlations
Click cells to compare fundamentals
Tandem Diabetes Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Tandem Diabetes fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 326.1M | 716.4M | 905.1M | 1.1B | 952.7M | 1.0B | |
Other Current Liab | 71.5M | 61.1M | 75.1M | 64.5M | 67.6M | 34.3M | |
Total Current Liabilities | 99.4M | 103.9M | 131.9M | 165.3M | 195.3M | 205.0M | |
Total Stockholder Equity | 195.0M | 366.3M | 433.1M | 439.9M | 313.6M | 160.8M | |
Other Liab | 17.7M | 27.4M | 34.8M | 36.1M | 41.5M | 43.6M | |
Property Plant And Equipment Net | 48.5M | 69.8M | 77.9M | 179.2M | 164.3M | 172.5M | |
Net Debt | (30.8M) | 133.7M | 243.5M | 247.4M | 356.8M | 374.6M | |
Retained Earnings | (624.8M) | (659.2M) | (634.6M) | (729.2M) | (951.8M) | (904.2M) | |
Accounts Payable | 17.7M | 17.8M | 28.0M | 55.7M | 49.6M | 52.1M | |
Cash | 51.2M | 94.6M | 71.2M | 172.5M | 58.9M | 65.4M | |
Non Current Assets Total | 50.0M | 79.2M | 93.6M | 202.8M | 204.7M | 214.9M | |
Non Currrent Assets Other | 708K | 580K | 9.1M | 19.0M | 5.2M | 4.3M | |
Other Assets | 708K | 29.2M | 9.1M | 10.7M | 12.3M | 12.9M | |
Cash And Short Term Investments | 176.5M | 484.9M | 623.8M | 616.9M | 467.9M | 242.0M | |
Net Receivables | 46.6M | 82.2M | 110.7M | 114.7M | 105.6M | 110.8M | |
Common Stock Total Equity | 59K | 14.3M | 64K | 65K | 74.8K | 71.0K | |
Common Stock Shares Outstanding | 58.5M | 61.0M | 64.3M | 64.1M | 65.0M | 68.2M | |
Short Term Investments | 125.3M | 390.3M | 552.6M | 444.4M | 409.0M | 429.5M | |
Liabilities And Stockholders Equity | 326.1M | 716.4M | 905.1M | 1.1B | 952.7M | 1.0B | |
Non Current Liabilities Total | 31.7M | 246.3M | 340.2M | 447.5M | 443.8M | 466.0M | |
Inventory | 49.1M | 63.7M | 68.6M | 111.1M | 157.9M | 165.8M | |
Other Current Assets | 4.0M | 12.8M | 16.9M | 7.2M | 16.6M | 17.4M | |
Other Stockholder Equity | 819.6M | 1.0B | 1.1B | 1.2B | 1.3B | 669.8M | |
Total Liab | 131.1M | 350.1M | 472.0M | 612.8M | 639.0M | 671.0M | |
Property Plant And Equipment Gross | 48.5M | 50.0M | 77.9M | 179.2M | 217.1M | 228.0M | |
Total Current Assets | 276.1M | 637.2M | 811.5M | 850.0M | 748.0M | 785.4M | |
Accumulated Other Comprehensive Income | 122K | 220K | (616K) | (1.8M) | 1.4M | 1.4M | |
Common Stock | 59K | 62K | 64K | 65K | 66K | 41.6K | |
Property Plant Equipment | 32.9M | 50.0M | 50.4M | 68.6M | 78.8M | 82.8M | |
Current Deferred Revenue | 3.9M | 6.1M | 10.2M | 18.8M | 44.0M | 46.2M | |
Intangible Assets | 777K | 8.8M | 6.6M | 4.6M | 2.8M | 3.5M | |
Net Tangible Assets | 195.0M | 366.3M | 433.1M | 439.9M | 505.9M | 531.2M | |
Retained Earnings Total Equity | (624.8M) | (659.2M) | (634.6M) | (729.2M) | (656.3M) | (689.1M) | |
Capital Surpluse | 819.6M | 1.0B | 1.1B | 1.2B | 1.3B | 776.1M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out World Market Map to better understand how to build diversified portfolios, which includes a position in Tandem Diabetes Care. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tandem Diabetes. If investors know Tandem will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tandem Diabetes listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.37) | Earnings Share (1.94) | Revenue Per Share 13.082 | Quarterly Revenue Growth 0.314 | Return On Assets (0.1) |
The market value of Tandem Diabetes Care is measured differently than its book value, which is the value of Tandem that is recorded on the company's balance sheet. Investors also form their own opinion of Tandem Diabetes' value that differs from its market value or its book value, called intrinsic value, which is Tandem Diabetes' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tandem Diabetes' market value can be influenced by many factors that don't directly affect Tandem Diabetes' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tandem Diabetes' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tandem Diabetes is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tandem Diabetes' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.